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Background. In some asthmatics the food allergy, for example, to milk, can participate in their bronchial complaints. The role
of food allergy should be conﬁrmed deﬁnitively by food ingestion challenge performed by an open challenge with natural foods
(OFICH) or by a double-blind placebo-controlled food challenge (DBPCFC). Objectives. To investigate the diagnostic value of
these techniques for conﬁrmation of a suspected milk allergy in bronchial asthma patients. Methods. In 54 asthmatics with a
positive history and/or positive skin tests for milk the 54 OFICH, and DBPCFC, were performed in combination with spirometry.
Results. The 54 patients developed 39 positive late asthmatic responses (LAR) and 15 negative asthmatic responses to OFICH and
40 positive LARs and 14 negative responses to DBPCFC. The overall correlation between the OFICH and DBPCFC was statistically
signiﬁcant (P<0.01). Conclusions. This study has conﬁrmed the existence of LAR to milk ingestion performed by OFICH and
DBPCFC in combination with spirometry. The results obtained by both the techniques did not diﬀer signiﬁcantly. The OFICH
with natural food combined with monitoring of objective parameter(s), such as spirometry, seems to be a suitable method for
detection of the food allergy in asthmatics. The DBPCFC can be performed as an additional check, if necessary.
1.Introduction
Food allergy is a clinical manifestation of an immunologic
process in which foods or their components acting as
antigen(s) stimulate the production of speciﬁc antibodies
or sensitize the particular T lymphocyte subsets and then
interact with them [1–11]. This interaction then induces a
number of intracellular and extracellular processes, deﬁned
as a hypersensitivity mechanism(s), resulting in the manifes-
tation of the clinical symptoms [1–23].
Principally, various types of hypersensitivity can be
involved in food allergy; however, the immediate type (IgE-
mediated) hypersensitivity has mostly been investigated and
documented [1–9, 11–19, 24–28]. Nevertheless, in recent
y e a r se v i d e n c eh a sb e e nf o u n df o rp o s s i b l ei n v o l v e m e n to f
other hypersensitivity types, such as late type (Type III) and
delayed type (Type IV) in the food allergy [1–3, 5–8, 14, 15,
23, 24, 29–39]. The exact immunopathologic mechanisms
underlyingvariousclinicalmanifestationsoffoodallergyare,
however, not yet fully clariﬁed [1–3, 7–9, 15].
Food allergy can occur in two basic forms: a primary
form, where the foods act as the primary and sole cause
of the activation of the immunologic mechanism(s), and
a secondary form, where food participates in an already
existing hypersensitivity mechanism(s) activated by diﬀerent
antigens,forexample,inhalantantigens.Thesecondaryform
occurs more frequently [1, 6–9, 11, 18, 40, 41]. Although the
provocation tests with foods are not always performed rou-
tinely,theymaybeconsideredtobethedeﬁniteconﬁrmation
ofinvolvementofparticularfoodsinthepatient’scomplaints
[1–13, 18, 20, 22, 25, 27, 28, 40, 42–51].
Provocation tests with foods can be performed using
three basic techniques, the open food ingestion challenge
(OFICH), double-blind placebo-controlled food challenge
(DBPCFC), and the single-blind food ingestion challenge
(SBFIC), all of them having a number of advantages and
disadvantages [1–13, 18–22, 25–28, 40, 42–58].
The DBPCFC is generally considered to be “a golden
standard” [1–13, 16, 25–28, 48, 49, 51, 58]. However, under
somecircumstancesandforsomereasonstheOFICHmaybe
more preferable to DBPCFC [1, 2, 6–11, 20–22, 25, 40, 43–
46, 52, 53]. The purpose of this study was (a) to verify the
possible involvement of milk allergy in some patients with
bronchialasthma,(b)tocomparetheresultsattainedbyboth2 Journal of Allergy
Table 1: Characteristics of the patients and control subjects.
Patients Control subjects
Total LAR NAR
n = 54 n = 39 n = 15 n = 12
Age (years) 31 ± 63 0 ± 73 2 ± 52 7 ± 6
Gender (M/F) 25/29 11/15 14/14 5/7
Disease history (years) 4.7 ± 1.3 3.5 ± 1.6 5.1 ± 1.0 4.2 ± 1.5
Asthmatic attacks per month 4 ± 15 ± 22 ± 13 ± 2
FEV1 (% predicted) 94.8 ± 4.2 93.1 ± 5.5 97.0 ± 3.3 95.6 ± 4.3
FVC (% predicted) 99.2 ± 1.1 96.4 ± 3.0 100.1 ± 1.4 98.0 ± 4.3
Blood leukocyte count (×109/L)• 7.1 ± 0.8 7.5.0 ± 1.2 8.0 ± 0.4 7.9 ± 1.5
Blood eosinophil count (×106/L)•• 355 ± 60 387 ± 56 329 ± 70 410 ± 53
Blood neutrophil count (×109/L)••• 5.2 ± 0.5 6.0 ± 0.3 4.5 ± 0.9 6.5 ± 0.4
Bronchial histamine threshold (BHT) 
≤2.0mg/mL 4 2 1
4.0mg/mL 9 2 4
8.0mg/mL 11 3 3
16.0mg/mL 4 5 2
32.0mg/mL 5 2 2
>32.0mg/mL 6 1 0
Values: mean ± SD; •:n o rm a lv a l u e= 4.0 − 10.0× 109/L; ••:n o rm a lv a l u e≤ 300 × 106/L; •••:n o rm a lv a l u e :2 . 0 −7.2 × 109/L; :n o rm a lv a l u e≥ 32.0mg/mL.
the techniques, OFICH and DBPCFC, and to assess their
suitability and diagnostic values for the conﬁrmation of food
allergy involvement in patients with bronchial asthma, by
monitoring the objective parameters, such as lung function
using spirometry.
2.MaterialandMethods
2.1. Patients. Fifty-four patients suﬀering from perennial
bronchial asthma suspected of participation of milk allergy,
examined at our Department of Allergology & Immunology,
Institute of Medical Sciences “De Klokkenberg,” Breda, The
Netherlands, and developing 39 positive late or 15 negative
asthmatic responses to OFICH, volunteered to participate in
this study.
These patients, 18–39 years of age, included 46 subjects
suﬀering from already existing bronchial asthma due to var-
ious inhalant allergens in whom the milk has been suspected
to participate possibly in their bronchial complaints and/or
demonstrating positive skin tests with milk and 8 subjects
in whom the milk has been suspected to be a sole cause of
their bronchial complaints. They showed positive skin (prick
and/or intradermal) tests with milk to various degrees, and
in some of them also positive speciﬁc IgE antibodies for
some foods have been recorded (Tables 1 and 2). They did
not suﬀer from any airway infections and did not use oral
corticosteroids or immunotherapy.
The patients were examined by routine diagnostic proce-
dure, acting also as an exclusion-inclusion check, consisting
of (1) general part: disease history, physical examination,
basic laboratory tests, X-ray of the chest and sinuses, lung
function, blood gases determination, bacteriological exam-
ination of the sputum; (2) allergologic part: skin tests with
inhalant and food allergens, bronchial histamine thresholds
[59],bloodleukocytediﬀerentialcount,determinationofthe
serum immunoglobulins; (3) 95 bronchial provocation tests
(BPT) with inhalant allergens [60–63]; (4) 54 OFICH with
milk suspected from history and/or positive skin tests. The
54 food challenges with milk were then repeated by means of
DBPCFC. A 5-day interval was always inserted between the
consecutive tests to prevent the carryover eﬀects and to allow
the patient’s recovery.
All challenges were performed in a period without
manifest symptoms and during a short hospitalization of the
patients. The milk and all dairy products were avoided by the
patients for 3-4 weeks before the challenges.
Inhaled glucocorticosteroids (n = 35), long-acting β2-
sympathomimetics (n = 19), and oral cromolyn (n =
2) were withdrawn 4 weeks, inhaled cromolyn (n = 5),
nedocromil sodium (n = 11), and leukotriene modiﬁers
(n = 1) 2 weeks, and other treatments 48 hours before each
of the challenges. The local ethical committee approved this
study, and informed consent was obtained from all study
participants.
2.2. Allergens. Dialyzed and lyophilized extracts of inhalant
allergenaswellasfoods(Allergopharma,Reinbek,Germany)
diluted in PBS were used for skin tests in concentrations
50–500BU/mL, as indicated in the subsection “Skin tests.”
The recommended concentrations by the manufacturer were
100–500BU/mL for skin prick as well as for intracutaneous
tests.
2.3. Skin Tests. The skin prick tests (SPTs) in concentrations
of500BU/mLwereperformed[27,28,59,64,65],andevalu-
atedafter20 minutes and 24 hours. If the SPTswerenegative,
then intracutaneous (intradermal) tests in concentrations ofJournal of Allergy 3
Table 2: Survey of other diagnostic parameters.
Patients Control subjects 
Total LAR NAR
n = 54 n = 39 n = 15 n = 12
Bronchial complaints  
(i) Dyspnea ++ 0 0
(ii) Wheezing ++ 0 0
(iii) Cough ± 00
(iv) Expectoration 0 0 0
Positive skin response (SPT)♦
(i) Immediate 31 24 7 1◦
Negative skin response (SPT)♦ 23 15 8 11
Positive skin response (i.c.)♦♦ 37 28 9 0
(i) Immediate −15 −12 −3
(ii) Late −21 −15 −6
(iii) Delayed −1 −1 −0
Negative skin response (i.c.) 17 11 6
Increased total IgE (serum)   110 0
Positive speciﬁc IgE (serum)    972 1
Increased total IgG (serum)• 220 0
Increased sub-classes (serum)••
(i) IgG1 110 0
(ii) IgG2 000 0
(iii) IgG3 000 0
(iv) IgG4 211 0
Increased total IgM (serum)••• 000 0
Increased total IgA (serum)  330 0
Concomitant (allergic) disease
(i) Allergic rhinitis 8 4 4 1
(ii) Atopic eczema 11 9 2 0
(iii) Urticaria 1 0 1 0
(iv) Angio-neurotic edema 0 0 0 1
(v) Gastrointestinal complaints 5 3 2 0
L: late asthmatic response; N: negative asthmatic response;  : Bronchial complaints accompanying the asthmatic response (author’s modiﬁed score system):
0: absent, ±: very slight/incidental, +: slight, ++: moderate/intermittent, +++: pronounced/regularly, ++++: very pronounced/distinct/frequent; ♦:s k i n
prick test (SPT) with milk extract; ♦♦: intracutaneous (intradermal) skin test with milk extract;   : total IgE in the serum (PRIST)-normal value ≤
500IU/mL;    : positive allergen-speciﬁc IgE in the serum for milk (ImmunoCAP) ≥ 0.70U/mL (=more than class 1); •: total IgGin the serum (Single
radial immunodiﬀusion and ELISA)-normal value ≤ 15.0g/L; ••:n o r m a lv a l u e s :I g G 1 < 5.0g/L,IgG2 < 2.6g/L, IgG3 < 0.4g/L, IgG4 < 0.5 g/L; •••:I g M≤
3.8g/L (<1.5);  :I g A≤ 4.0g/L (<3.2);  : control subjects: 6 open (OFICH) + 6 double-blind (DBPCFC) food ingestion challenges with milk;  :p o s i t i v e
skin response to milk extract.
100BU/mL and 500BU/Ml were carried out [1, 6–10, 18–
22, 28, 57, 60–65] and evaluated 20 minutes, 6, 12, 24, 36, 48,
72, and 96 hours after the injection. If the SPT were positive
(immediate/early skin response), then the intracutaneous
tests were performed in concentrations of 50BU/mL and
200BU/mL and evaluated 20 minutes, 6, 12, 24, 36,48, 72
and 96 hours after the injection. Histamine diphosphate
was used as a positive control, whereas PBS was used as
a negative control. A skin wheal (>7.0mm in diameter)
appearing 20 minutes after the injection was considered to
be positive immediate skin response, the skin inﬁltration
observed between 6 and 12 hours was considered to be a late
skin response, and the skin induration recorded later than 48
hours was designated a delayed skin response [6–10, 60–65].
2.4. Spirometry. The asthmatic responses were monitored by
using spirometry (Spirograph D-75; Lode NV, Groningen,
The Netherlands), recording the FVC and FEV1,a n de v a l u -
ated by the following criteria: (1) the decrease in FEV1 of less
than 10% with respect to the prechallenge values as negative,
from10%to20%asdoubtful,andof20%ormoreaspositive
asthmatic response; (2) the decrease in FEV1 values recorded
at least at 3 consecutive time intervals was considered to
be a positive response; (3) the response appearing within 2
hours after the challenge was considered to be an immediate
asthmatic response (IAR), that occurring between 4 and 24
hours to be a late/asthma response (LAR), and response
appearing later than 24 hours after the challenge to be a
delayed asthmatic response (DYAR) [9, 18, 22, 60–63].
2.5. Food Used for the Ingestion Challenge. The quantities of
milk used both for the OFICH and DBPCFC were similar
to those consumed usually by the patients in order to
obtain the highest degree of reproducibility. The amount4 Journal of Allergy
of 100mL of natural milk (3.5g of protein and 3.5g of fat
per 100mL) was used for the OFICH. The amount of 20g
of powdered whole milk (containing 3.0g of protein and
2.9g of fat) dissolved in 80mL water was used for DBPCFC.
The 5% glucose solution was used as control (placebo) for
OFICH. For the DBPCFC, 20g of tablet inactive ingredients,
so-called “excipients” (including lactose, dibasic calcium,
sucrose, maize corn, starch, and microcrystalline cellulose)
dissolvedin80mLwater,wasusedascontrol(placebo).Both
the solutions used for DBPCFC, the powdered milk as well
as the inactive tablet mass (excipients) were enriched with
4g of glucose to mask their taste. The control challenges
were performed according to the same schedule as those
with the experimental foods. The DBPCFC arrangement was
in principle triple-blinded, and that both for the technician
preparing the test material, and for the nurse performing the
challenge, and lastly for the patient himself.
2.6. Schedule of the Food Challenge. The OFICH and
DBPCFC challenges as well as the spirometry monitoring of
wereperformedaccordingtotheEuropeanandinternational
standard procedures [2, 4, 25–27, 40, 42, 48, 49, 57, 58]
modiﬁed by us [6–10, 18–22], by the following schedule:
(1) recording of the initial (baseline) values at 0, 5 and
10 minutes; (2) ingestion of the food within 10 minutes,
followed by a 1-hour waiting interval to allow the food to be
ingested. During this interval the parameters were measured
four times to exclude an unexpected or too early reaction;
(3) recording of the postchallenge values at 0, 5, 10, 20, 30,
45, 60, 90, and 120 minutes, and every hour up to the 12th
hour and every second hour during the 22nd and 38th hour,
the 46th and 58th hour intervals [6–10, 18–22].
2.7. Control Group. Twelve patients suﬀering from perennial
bronchial asthma, developing 12 late asthmatic responses
(LAR)toBPTwithDermatophagoidespteronyssinus,ho wev er
demonstrating negative history, skin test, and RAST for the
foods,volunteeredtoparticipateascontrols.In6patientsthe
OFICH and in 6 patients the DBPCFC were performed with
the most frequently consumed food, usually milk, cheese or
peanuts, according to the same schedule as applied in the
patients studied.
2.8. Statistical Analysis. Asthmatic responses were ana-
lyzed by generalized multivariate analysis of the variance
(MANOVA) model [66]. The polynomials were ﬁtted to the
mean curves over time (8 time points within 120 minutes
and 14 time points up to 24 hours after the challenge),
and the appropriate hypotheses were tested by the modiﬁed
MANOVA computerized system.
In every patient the postchallenge FEV1 values measured
at each time interval were compared with the prechallenge
values and evaluated by Wilcoxon matched-pair signed-
rank test. The mean postchallenge FEV1 values were com-
pared with corresponding post-challenge control values
at each of the time points and analyzed by the Mann-
Whitney U test. The correlation between the OFICH and
DBPCC was evaluated by Wilcoxon matched-pair signed
rank test. A P value < 0.05 was considered to be statistically
signiﬁcant.
3. Results
In 54 patients suﬀering from bronchial asthma, 54 open
ingestion challenges with milk (OFICH) have resulted in 39
positive asthmatic responses of late type (LAR; P<0.01) and
15 negative asthmatic responses (NAR; P>0.1) (Table 1,
Figures 1 and 2). The LARs began 4–6 hours, reached their
maximum6–10hours,andresolvedwithin24hoursafterthe
milkingestionchallenge(OFICH).TheLARswereassociated
with various general and bronchial complaints, predom-
inantly dyspnea (100%), wheezing (79%), cough (28%),
oral itching (23%) and gastrointestinal complaints (31%)
(Table 2), whereas no general or bronchial complaints were
recorded during the NARs. The LARs as well as the NARs
correlated with disease history, skin tests and other diagnos-
tic parameters to various degrees (Tables 1, 2,a n d3). The 39
patients developing positive LAR for milk in OFICH demon-
strated positive skin tests, and positive (suspect) history in
48%, positive skin tests but unknown history in 4%, and
positive (suspect) history but negative skin tests in 20%. The
15 patients developing negative asthmatic response (NAR)
for milk in OFICH displayed positive skin test and suspect
historyin11%,positiveskintestbutunknownhistoryin6%,
and suspect history but negative skin tests in 11% (Tables 3
and 4). Survey of detailed agreement between the positive
and negative asthmatic responses to OFICH with milk and
the other diagnostic parameters (disease history, skin tests)
in both the groups of patients, those with bronchial asthma
to inhalant allergens and suspicion of milk allergy as well as
thosewithbronchialasthmasuspectedofmilkallergyonly,is
presented in Table 5. All 54 control ingestion challenges with
glucose solution were negative (P>0.1) and without any
accompanying bronchial or general complaints.
The 54 patients challenged with milk by means of
DBPCFC developed 40 positive LAR (P<0.01) and 14 NAR
(P>0.05) (Table 6, Figures 1 and 2). The 38 of the 40
DBPCFC positive LARs correlated with the OFICH positive
LARs (=97%; P<0.01), whereas 13 of the 14 DBPCFC nega-
tive responses (NARs) correlated with the OFICH negative
responses (NARs) (=87%; P<0.05).
The 3 noncorrelating cases showed 2 OFICH negative
responses but DBPCFC positive LARs and 1 OFICH positive
LAR but DBPCFC negative response. The overall correlation
between the OFICH and DBPCFC responses was statistically
signiﬁcant (P<0.01). All 54 DBPCFC control challenges
with “tablet excipients” were negative (P>0.1). No bro-
nchial complaints were registered during the DBPCFC
controls; however 1 patient developed diarrhea to a slight
degree during this test (=2%).
3.1. Control Group. The 12 patients of the control group, in
whom6OFICHsand6DBPCFCswithmilkwereperformed,
did not develop any asthmatic response. No general or
bronchial complaints have been registered during these 12
NAR (P>0.2).Journal of Allergy 5
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Figure 1: Late asthmatic responses due to the food ingestion challenge (LAR) in 39 patients with bronchial asthma. The mean percentage
changes in the FEV1 calculated from all patients with positive LAR. LAR (n = 39) recorded after OFICH: experimental food () and control
food (x) and after DBPCFC: experimental food () and placebo (+) I: initial (baseline) values; food ingestion: OFICH or DBPCFC; waiting
interval: 1 hour; bars: means ± SEM.
4. Discussion
The role of foods and food allergy in bronchial asthma in
producing bronchial complaints, especially bronchospasm,
through the hypersensitivity mechanisms has already been
investigated from various points of views [1–9, 11–13, 15,
16, 18, 20, 22, 26, 42, 45, 53, 55, 56, 67]. The involvement
of food allergy in bronchial asthma, classically attributed
to the IgE-mediated hypersensitivity upon involvement of
IgE antibodies, mast cells, basophils, eosinophils, and Th2
lymphocytes, has mostly been investigated [1–3, 5, 9, 11–13,
15, 16, 24, 26, 29, 39, 44, 67]. Later, some evidence was also
gathered for possible involvement of the non-IgE-mediated
mechanism(s) upon participation of various cytokines,
neutrophils, and Th1 lymphocytes in the food allergy events
[5–9, 14, 15, 23, 24, 29–39, 43, 53, 54, 68, 69]. The link
between the BALT and GALT and the disturbed homing of T
andBlymphocytes(plasmacells)mayalsoplayanimportant
role in these processes [1, 14, 15, 24, 29, 33, 39, 68, 69].
Patients with bronchial asthma upon participation of
foodallergy,havingbeenchallengedwithfoods,maydevelop
various types of asthmatic (bronchus-obstructive) response.
The immediate/early (IAR), late (LAR), and delayed (DYAR)
asthmatic responses to food ingestion challenge, described
in our previous papers [9, 18, 20, 22] and some of these
types reported also by other investigators [1–3, 11–13, 16,
20, 43–46, 53, 55, 56, 70], are in principle analogical to the
three types of asthmatic response to the bronchial challenge
with inhalant allergens [60–63]. The IAR, LAR and DYAR
due to the food ingestion challenge diﬀer substantially not
only with respect to the possibly underlying immunologic
mechanisms, but also in their clinical features, time course
and association with other diagnostic parameters [1, 2, 7–
9, 12, 13, 15, 18, 20, 22–24, 30–33, 38, 39, 53–56, 70].
The immediate/early asthmatic response (IAR/EAR) to
foods, due to the immediate (IgE-mediated) hypersensitivity
mechanism, has been investigated most frequently [1–5,
9, 11–13, 16, 24, 26, 39, 40]. The late asthmatic response
to foods (LAR) has also been reported in the literature
[53, 55, 56, 70]. However, the immunologic mechanism(s)
underlying the LAR, especially the possible involvement of
IgE-mediated or non-IgE-mediated hypersensitivity, is not
yet suﬃciently clariﬁed [2, 9, 15, 23, 24, 29, 39]. In our
previous studies we also have observed and described the
DYAR response to food ingestion challenge, analogical to the
DYARtobronchialchallengewithinhalantallergens[63,71],
in which the involvement of cell-mediated hypersensitivity
mechanism (Type IV allergy) could be presumed [9, 15, 18,
20, 22, 63]. This presumption may be supported by other
investigators’ ﬁndings of possible role of various cell types,
such as Th1-cells, neutrophils, macrophages, dendritic cells,
and a number of cytokines, chemokines, and other factors,6 Journal of Allergy
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Figure 2: Negative asthmatic responses due to the food ingestion challenge (NAR) in 15 patients with bronchial asthma. The mean
percentage changes in the FEV1 calculated from all patients with NAR. NAR (n = 39) recorded after OFICH: experimental food ()a n d
control food (x) and after DBPCFC: experimental food () and placebo (+) I: initial (baseline) values; food ingestion: OFICH or DBPCFC;
waiting interval: 1 hour; bars: means ± SEM.
in the clinical manifestations of food allergy, especially in
its role in bronchial asthma [2, 14, 15, 24, 29–31, 33–38,
53, 54, 56]. However, there is still a dearth of information
concerning the clinical features of the various types of
bronchial response resulting from the ingestion (challenge)
as well as their association and correlation with other in vivo
and in vitro diagnostic parameters in large groups of well-
deﬁned patients [1, 2, 6–9, 11–13, 40, 41, 43, 45, 47, 49, 67].
Diagnostic conﬁrmation of the involvement of food
allergy in the clinical manifestations, especially in the
bronchial asthma, is not always an easy assignment. The
diagnosticparametersbeingcustomarilyusedinthepractice,
such as disease history, skin tests, determination of the total
and speciﬁc IgE antibodies in the serum (PRIST, RAST,
ImmunoCAP), demonstrate various degrees of correlation
with the clinical manifestations due possibly to food allergy,
such as bronchial asthma. None of these parameters demon-
strated suﬃcient and statistically signiﬁcant diagnostic value
to predict and/or to conform arbitrarily the role of foods
and food allergy in bronchial asthma in a given patient [1–
13, 18, 27, 28, 41–43, 45, 58, 67, 72].
The role of foods in the bronchial asthma can deﬁnitely
be conﬁrmed only by the ingestion challenge with the
suspected food(s), during which the particular asthmatic
response types can be recorded quantitatively in its dynamic
course[1, 2, 7–9, 12, 18, 22, 25, 27, 28, 42–44, 46, 48–
50, 53]. The food challenge is therefore a more reliable test
for the detection of a bronchial reaction to foods and its
clinical consequences than data obtained from single skin
tests and/or RAST/ImmunoCAP tests [1, 2, 9, 12, 18, 22, 26,
39, 42, 44–48, 50, 57, 58, 72].
The importance and signiﬁcance of the food challenge
for the diagnostic conﬁrmation of the food allergy has
repeatedly been demonstrated in the literature [1–13, 16–
22, 25–28, 30, 39, 40, 42–46, 48–50, 52–55, 57, 58, 70, 72].
Unfortunately, papers dealing with the role of food allergy
and food ingestion challenge in patients with bronchial
asthma are not numerous [2, 9, 11–13, 16, 18–22, 26, 27, 42,
50, 52, 57, 58].
Nevertheless, the food ingestion challenge has also some
limitations and contraindications and requires therefore
some special conditions, and precautions [1, 2, 6, 9, 11,
13, 22, 24, 28, 40, 42–45, 47–50, 52, 57, 58]. The absolute
contraindication is the suspected anaphylactic shock to
the particular food(s), pregnancy, and any life-threatening
disorder or situation, whereas the relative contraindication
may be considered any state or disorder leading to any
undesirable complication(s) or which can distinctly inﬂu-
ence the food ingestion challenge results, such as treatment
with certain drugs [1, 2, 6, 9, 22, 27, 28, 40, 42, 45, 48,
49, 52, 57, 58]. Food challenges, where the vital organ
functions should be recorded, for example, lung function,Journal of Allergy 7
Table 3: Agreement between OFICH and other diagnostic parameters.
History + Skin +(n = 32) History − Skin +(n = 5) History + Skin −(n = 17) Total (n = 54)
OFICH (n = 54)
(i) 39 positive responses 26 (48%) 2 (4%) 11 (20%) 39 (72%)
(ii) 15 negative responses 6 (11%) 3 (6%) 6 (11%) 15 (28%)
Total 32 (59%) 5 (10%) 17 (31%) 54 (100%)
Table 4: Survey of detailed agreement between asthmatic response
types to milk ingestion challenge (OFICH) recorded in patients of
both the groups and other diagnostic parameters (disease history
and skin tests) for milk.
Asthmatic responses to OFICH with milk
Total LAR NAR
Patients n = 54 n = 39 n = 15
G r o u pI .( n = 46)
(i) History + Skin + 26 21 5
(ii) History + Skin − 15 9 6
(iii) History − Skin + 5 2 3
46 32 14
Group II. (n = 8)
(i) History + Skin + 6 5 1
(ii) History + Skin − 22 0
(iii) History − Skin + 0 0 0
87 1
Group I: patients with already existing bronchial asthma to inhalant
allergens and additional suspicion of milk allergy.
Group II: patients in whom the milk allergy has been suspected to be a sole
cause of their bronchial complaints.
+:suspectorpositive; −:unknownornegative;OFICH:openfoodingestion
challenge with milk.
severe diarrhea, or where a late onset of the response is
expected, should be performed during hospitalization under
standard conditions, and for a suﬃc i e n t l yl o n gp e r i o do f
time, 56 hours at least [1, 6, 9, 22, 25, 27, 40, 48, 52, 53].
The foods, their parts and the related foods used for the
ingestion challenge should be excluded from the diet for a
suﬃciently long period of time before the challenge, at least
7–14 days [1, 2, 6, 9, 18–22, 25, 27, 28, 40, 42, 45, 46, 48, 49,
52, 58].
The food ingestion challenge can be performed by an
openchallenge(OFICH)withnaturalfoods,bydouble-blind
placebo-controlled challenge (DBPCFC), or rarely by single-
blind challenge (SBFIC), each of them having its advantages
and disadvantages [1–13, 16, 18–22, 24–28, 39, 40, 42–
52, 57, 58, 67, 70].
The OFICH with natural foods and suitable placebo is
relatively simple easy to perform, the results are directly
available, and no special processing of the foods used for the
challenge is required. In addition, it is eligible in cases where
the objective parameters can be recorded. This technique is
notsuitableforchallengeswheretheresultscanbeinﬂuenced
by the patient or by the investigator or where the response
can only be measured by means of subjective parameters,
such as headache, (skin) itching, tiredness, and behavior
changes [1–3, 6–11, 16, 22, 27, 42, 45, 48, 49, 52, 73].
The DBPCFC, considered by many investigators to be
a “golden standard,” has a number of advantages as well
as disadvantages [1–9, 25, 27, 42, 43, 48, 49, 51, 52, 57].
Its important advantage is exclusion of the inﬂuencing of
results both by the patient and investigator, its usability in
cases where the objective parameters cannot be recorded and
the response can only be evaluated by means of subjective
parameters, such as pain, headache, itching, gastrointestinal
complaints, general malaise, behavior changes, and ﬁnally
when the eﬀects of drugs should be investigated [1–9, 25, 27,
28, 40, 42, 43, 46, 48, 49, 51, 52, 58].
Nevertheless,thistechniquehasalsosomedisadvantages,
such as (a) processing of the food in a manner excluding
its identiﬁcation, which means the food must be colorless,
tasteless, odorless. Such a preparation of foods can lead
to essential changes of their structure and physical and/or
chemical properties and sometimes it is not even possible;
(b) providing a suitable placebo that matches the oﬀend-
ing food in quantity and other properties is sometimes
a technical problem; (c) the content of the capsules to
be swallowed is maximally 500mg; If the foods tested
were administered in an amount equal to that used in
a daily practice then the capsule number would increase
enormously, otherwise the food will be taken in an amount
lessthanthenaturalconsumption;(d)thefoodadministered
in capsules excludes the oral cavity, tongue and oesophagus,
organs which are often the site of the ﬁrst reaction to foods;
(e)byadministeringoffoodincapsules,thedigestiveprocess
already beginning in the mouth is shifted to the gastric and
duodenal mucosa and therefore prolonged; (f) the hidden
placebo can sometimes induce a false-positive response [1–
9, 25, 27, 42, 43, 48, 49, 51, 52, 57, 58].
The results of this study conﬁrmed the existence of late
type of asthmatic response (LAR) due to the food ingestion,
which has already been described in our previous studies
[7–9, 18, 20, 22] and reported by other authors [53, 55,
56, 70]. Although a possible role of an “IgE-mediated”
hypersensitivity in the LAR caused by food allergy has
already been suggested, the precise mechanism underlying
this asthmatic response type is not yet suﬃciently clariﬁed
[1–3, 5, 9, 13, 17, 18, 24, 27, 29, 34–39, 49, 53–55, 70].
These results have emphasized the importance of the food
ingestion challenge for the diagnosis of food allergy in
patients with bronchial asthma. The deﬁnite conﬁrmation of
this role should be provided by a food ingestion challenge
combined with monitoring of lung function, for example,8 Journal of Allergy
Table 5: Survey of the asthmatic responses to inhalant allergens in patients developing positive and negative asthmatic response to OFICH
with milk.
Patients developing asthmatic response to OFICH with milk
Total LAR NAR
n = 54 n = 39 n = 15
Group I (n = 46)
Total bronchial challenge with inhalant allergens 72 53 19
(i) Positive asthmatic response 52 35 17
(ii) Negative asthmatic response 20 18 2
Group II (n = 8)
Total bronchial challenges with inhalant allergens 23 20 3
(i) Positive asthmatic response 3 1 2
(ii) Negative asthmatic response 20 19 1
Total BPT with inhalant allergens 95 73 22
Group I: patients with already existing bronchial asthma to inhalant allergens and additional suspicion of milk allergy.
Group II: patients in whom the milk allergy has been suspected to be a sole cause of their bronchial complaints.
+: positive; −: negative; OFICH: open food ingestion challenge with milk.
Table 6: Correlation between OFICH and DBPCFC.
DBPCFC (n −54)
Positive (n = 40) Negative (n = 14) Total
OFICH (n = 54)
(i) 39 positive OFICH 38∗∗ 13 9
(ii) 15 negative OFICH 2 13∗ 15
Total 40 14 54
OFICH: open food ingestion challenge; DBPCFC: double-blind placebo controlledfood challenge; Statistical signiﬁcance: ∗ < 0.05; ∗∗ < 0.01.
spirometry, demonstrating the particular types of asthmatic
response in their dynamic course.
Regarding the results of this study, together with our
previous papers [6–10, 18–22] and other investigators’ ﬁnd-
ings [2, 25, 28, 42–47, 49, 51, 53, 54, 57, 58] the diagnostic
value of the food ingestion challenge seems to be superior
to other diagnostic parameters. The signiﬁcant correlation
of the OFICH and DBPCFC results, both for the positive
and for the negative asthmatic responses would suggest that
in bronchial asthma, where the asthmatic responses can be
measured by means of objective lung function, the DBPCFC
is not superior to the OFICH [6–10, 20–22, 44–46, 52].
It can therefore be concluded that the OFICH combined
with monitoring of objective diagnostic parameters, such as
lungfunctions,canbeconsideredtobedeﬁniteconﬁrmation
of the suspected role of food allergy and involvement of
certain food(s), such as cow’s milk, in bronchial complaints
of patients suﬀering from bronchial asthma. These patients
may include both those suﬀering from bronchial asthma
due to the inhalant allergens, in whom the food allergy
is suspected as an additional cause of their bronchial
complaints,andthoseinwhomthefoodallergy,forexample,
for cow’s milk, is suspected as an only cause of the bronchial
asthma symptoms. The OFICH is a suitable and reliable
technique in all cases of food allergy where the response can
be measured by using the objective parameters and recorded
for a suﬃciently long period of time, such as 24–48 hours.
In such cases this technique would be preferable, because it
is easier, cheaper, quicker, and less burdening for the patient
who will not need to swallow a large number of capsules.
The DBPCFC should be reserved for such cases, in which
objective parameters cannot be measured; the response to
food can only be expressed by subjective complaints, for
example, itching, headache, tiredness, distinct discrepancy
amongtheotherdiagnosticparametersthatoccur,orincases
in which the OFICH results are dubious or not reliable. Vice
versa, in the cases in which the DBPCFC results seem to be
unreliable, the OFICH can be performed as an extra check.
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